Publication: Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
Loading...
Identifiers
Date
2019-01-09
Authors
Gavilá, Joaquín
Oliveira, Mafalda
Pascual, Tomás
Perez-Garcia, Jose
Gonzàlez, Xavier
Canes, Jordi
Paré, Laia
Calvo, Isabel
Ciruelos, Eva
Muñoz, Montserrat
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Description
MeSH Terms
Adult
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Cardiotoxicity
Chemotherapy, Adjuvant
Doxorubicin
Female
Humans
Middle Aged
Neoadjuvant Therapy
Paclitaxel
Polyethylene Glycols
Receptor, ErbB-2
Trastuzumab
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Cardiotoxicity
Chemotherapy, Adjuvant
Doxorubicin
Female
Humans
Middle Aged
Neoadjuvant Therapy
Paclitaxel
Polyethylene Glycols
Receptor, ErbB-2
Trastuzumab
DeCS Terms
CIE Terms
Keywords
Breast cancer, HER2, HER2-enriched, PAM50, cardiac safety, intrinsic subtypes, neoadjuvant